Topic: influenza

Thanks to widely used egg-based manufacturing, this fall's flu vaccine will be only 20% effective against the dominant strain, according to a study.

Novavax may be years away from a potential approval of its RSV vaccine, but executives aren't waiting to prepare for a possible rollout.

GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.

Topline phase 1/2 data showed NanoFlu elicited significantly higher antibody responses against multiple flu strains.

Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.

Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.

Vaccine protection against H3N2 viruses—the predominant strain that tends to cause more severe illness—was only 25% this year.

Here's some other vaccine news of note for the week.

Health experts presented flu vaccination guidelines stressing there's no difference in safety for shots given people allergic to eggs.

The egg-based production process might have made this season's flu shot only 10% effective.